Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 30;4(4):CD011459.
doi: 10.1002/14651858.CD011459.pub2.

Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia

Fionnuala Jordan  1 , Terry J Quinn  2 , Bernadette McGuinness  3 , Peter Passmore  3 , John P Kelly  4 , Catrin Tudur Smith  5 , Kathy Murphy  1 , Declan Devane  1
Affiliations

Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia

Fionnuala Jordan et al. Cochrane Database Syst Rev. .

Abstract

Background: Dementia is a worldwide concern. Its global prevalence is increasing. At present, there is no medication licensed to prevent or delay the onset of dementia. Inflammation has been suggested as a key factor in dementia pathogenesis. Therefore, medications with anti-inflammatory properties could be beneficial for dementia prevention.

Objectives: To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia.

Search methods: We searched ALOIS, the specialised register of the Cochrane Dementia and Cognitive Improvement Group up to 9 January 2020. ALOIS contains records of clinical trials identified from monthly searches of several major healthcare databases, trial registries and grey literature sources. We ran additional searches across MEDLINE (OvidSP), Embase (OvidSP) and six other databases to ensure that the searches were as comprehensive and up-to-date as possible. We also reviewed citations of reference lists of included studies.

Selection criteria: We searched for randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing aspirin or other NSAIDs with placebo for the primary or secondary prevention of dementia. We included trials with cognitively healthy participants (primary prevention) or participants with mild cognitive impairment (MCI) or cognitive complaints (secondary prevention).

Data collection and analysis: We used standard methodological procedures according to the Cochrane Handbook for Systematic Reviews of Interventions. We rated the strength of evidence for each outcome using the GRADE approach.

Main results: We included four RCTs with 23,187 participants. Because of the diversity of these trials, we did not combine data to give summary estimates, but presented a narrative description of the evidence. We identified one trial (19,114 participants) comparing low-dose aspirin (100 mg once daily) to placebo. Participants were aged 70 years or older with no history of dementia, cardiovascular disease or physical disability. Interim analysis indicated no significant treatment effect and the trial was terminated slightly early after a median of 4.7 years' follow-up. There was no evidence of a difference in incidence of dementia between aspirin and placebo groups (risk ratio (RR) 0.98, 95% CI 0.83 to 1.15; high-certainty evidence). Participants allocated aspirin had higher rates of major bleeding (RR 1.37, 95% CI 1.17 to 1.60, high-certainty evidence) and slightly higher mortality (RR 1.14, 95% CI 1.01 to 1.28; high-certainty evidence). There was no evidence of a difference in activities of daily living between groups (RR 0.84, 95% CI 0.70 to 1.02; high-certainty evidence). We identified three trials comparing non-aspirin NSAIDs to placebo. All three trials were terminated early due to adverse events associated with NSAIDs reported in other trials. One trial (2528 participants) investigated the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib (200 mg twice daily) and the non-selective NSAID naproxen (220 mg twice daily) for preventing dementia in cognitively healthy older adults with a family history of Alzheimer's disease (AD). Median follow-up was 734 days. Combining both NSAID treatment arms, there was no evidence of a difference in the incidence of AD between participants allocated NSAIDs and those allocated placebo (RR 1.91, 95% CI 0.89 to 4.10; moderate-certainty evidence). There was also no evidence of a difference in rates of myocardial infarction (RR 1.21, 95% CI 0.61 to 2.40), stroke (RR 1.82, 95% CI 0.76 to 4.37) or mortality (RR 1.37, 95% CI 0.78 to 2.43) between treatment groups (all moderate-certainty evidence). One trial (88 participants) assessed the effectiveness of celecoxib (200 mg or 400 mg daily) in delaying cognitive decline in participants aged 40 to 81 years with mild age-related memory loss but normal memory performance scores. Mean duration of follow-up was 17.6 months in the celecoxib group and 18.1 months in the placebo group. There was no evidence of a difference between groups in test scores in any of six cognitive domains. Participants allocated celecoxib experienced more gastrointestinal adverse events than those allocated placebo (RR 2.66, 95% CI 1.05 to 6.75; low-certainty evidence). One trial (1457 participants) assessed the effectiveness of the COX-2 inhibitor rofecoxib (25 mg once daily) in delaying or preventing a diagnosis of AD in participants with MCI. Median duration of study participation was 115 weeks in the rofecoxib group and 130 weeks in the placebo group. There was a higher incidence of AD in the rofecoxib than the placebo group (RR 1.32, 95% CI 1.01 to 1.72; moderate-certainty evidence). There was no evidence of a difference between groups in cardiovascular adverse events (RR 1.07, 95% CI 0.68 to 1.66; moderate-certainty evidence) or mortality (RR 1.62, 95% CI 0.85 to 3.05; moderate-certainty evidence). Participants allocated rofecoxib had more upper gastrointestinal adverse events (RR 3.53, 95% CI 1.17 to 10.68; moderate-certainty evidence). Reported annual mean difference scores showed no evidence of a difference between groups in activities of daily living (year 1: no data available; year 2: 0.0, 95% CI -0.1 to 0.2; year 3: 0.1, 95% CI -0.1 to 0.3; year 4: 0.1, 95% CI -0.1 to 0.4; moderate-certainty evidence).

Authors' conclusions: There is no evidence to support the use of low-dose aspirin or other NSAIDs of any class (celecoxib, rofecoxib or naproxen) for the prevention of dementia, but there was evidence of harm. Although there were limitations in the available evidence, it seems unlikely that there is any need for further trials of low-dose aspirin for dementia prevention. If future studies of NSAIDs for dementia prevention are planned, they will need to be cognisant of the safety concerns arising from the existing studies.

PubMed Disclaimer

Conflict of interest statement

FJ: none.

TQ: none.

BMcG: none.

PP: none.

JK: none.

CTS: none.

KM: none.

DD: none.

Figures

1
1
Study flow diagram. RCT: randomised controlled trial.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Aspirin compared with placebo, Outcome 1: Incidence of dementia
1.2
1.2. Analysis
Comparison 1: Aspirin compared with placebo, Outcome 2: Adverse events (haemorrhage)
1.3
1.3. Analysis
Comparison 1: Aspirin compared with placebo, Outcome 3: Mortality
1.4
1.4. Analysis
Comparison 1: Aspirin compared with placebo, Outcome 4: Activities of daily living
2.1
2.1. Analysis
Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's disease (AD), Outcome 1: Incidence of dementia (AD)
2.2
2.2. Analysis
Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's disease (AD), Outcome 2: All‐cause dementia
2.3
2.3. Analysis
Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's disease (AD), Outcome 3: Adverse effects – cardiovascular: myocardial infarction
2.4
2.4. Analysis
Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's disease (AD), Outcome 4: Adverse effects – stroke
2.5
2.5. Analysis
Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's disease (AD), Outcome 5: Adverse effects – congestive heart failure
2.6
2.6. Analysis
Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's disease (AD), Outcome 6: Adverse effects – transient ischaemic attack
2.7
2.7. Analysis
Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's disease (AD), Outcome 7: Adverse effects – antihypertensive therapy
2.8
2.8. Analysis
Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's disease (AD), Outcome 8: Mortality
2.9
2.9. Analysis
Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's disease (AD), Outcome 9: Cognitive decline from baseline
3.1
3.1. Analysis
Comparison 3: NSAIDs compared with placebo: adults with age‐related memory loss, Outcome 1: Adverse events – gastrointestinal
3.2
3.2. Analysis
Comparison 3: NSAIDs compared with placebo: adults with age‐related memory loss, Outcome 2: Cognitive decline from baseline (Psychomotor Speed)
3.3
3.3. Analysis
Comparison 3: NSAIDs compared with placebo: adults with age‐related memory loss, Outcome 3: Cognitive decline from baseline (Visuospatial Functioning)
3.4
3.4. Analysis
Comparison 3: NSAIDs compared with placebo: adults with age‐related memory loss, Outcome 4: Cognitive decline from baseline (Executive Functioning)
3.5
3.5. Analysis
Comparison 3: NSAIDs compared with placebo: adults with age‐related memory loss, Outcome 5: Cognitive decline (Learning)
3.6
3.6. Analysis
Comparison 3: NSAIDs compared with placebo: adults with age‐related memory loss, Outcome 6: Cognitive decline (Delayed Recall)
3.7
3.7. Analysis
Comparison 3: NSAIDs compared with placebo: adults with age‐related memory loss, Outcome 7: Cognitive decline (Language/Semantic Memory)
4.1
4.1. Analysis
Comparison 4: NSAIDs compared with placebo: mild cognitive impairment, Outcome 1: Incidence of dementia
4.2
4.2. Analysis
Comparison 4: NSAIDs compared with placebo: mild cognitive impairment, Outcome 2: Adverse events
4.3
4.3. Analysis
Comparison 4: NSAIDs compared with placebo: mild cognitive impairment, Outcome 3: Mortality
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

ADAPT Research Group 2007/2006 {published data only}
    1. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomised, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clinical Trials 2006;1(7):e33. [DOI: 10.1371/journal.pctr.0010033] - DOI - PMC - PubMed
    1. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007;68(21):1800-8. - PubMed
ASPREE 2018 {published data only}
    1. McNeil JJ, Woods RL, Nelson MR, Reid B, Kirpach R, Wolf R, et al. Effects of aspirin on disability-free survival in the healthy elderly. New England Journal of Medicine 2018;379:1519-28. - PMC - PubMed
Small 2008 {published data only}
    1. Small GW, Siddarth P, Silverman DH, Ercoli LM, Miller KJ, Lavretsky H, et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. American Journal of Geriatric Psychiatry 2008;16(12):999-1009. - PMC - PubMed
Thal 2005 {published data only}
    1. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30(6):1204-15. - PubMed

References to studies excluded from this review

ADAPT‐FS Research Group 2015 {published data only}
    1. ADAPT-FS Research Group. Follow-up evaluation of cognitive function in the randomized Alzheimer's disease anti-inflammatory prevention trial and its follow-up study. Alzheimer's & Dementia 2015;11(2):216-25. - PMC - PubMed
Arai 2011 {published data only}
    1. Arai H. A comprehensive strategy for dementia from primary prevention to end-stage management. Psychogeriatrics 2011;11(3):131-4. - PubMed
Arvanitakis 2008 {published data only}
    1. Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, Kelly JF, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008;70(23):2219-25. - PubMed
Bertozzi 1996 {published data only}
    1. Bertozzi B, Barbisoni P, Franzoni S, Frisoni GB, Rozzini R, Trabucchi M. Association of chronic non-steroidal anti-inflammatory drugs use and cognitive decline in non-demented elderly patients admitted to a Geriatric Evaluation and Rehabilitation Unit. Archives of Gerontology and Geriatrics 1996;23(1):71-9. - PubMed
Breitner 2009 {published data only}
    1. Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009;72(22):1899-905. - PMC - PubMed
Broe 2000 {published data only}
    1. Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Archives of Neurology 2000;57(11):1586-91. - PubMed
Bruce‐Jones 1994 {published data only}
    1. Bruce-Jones PN, Crome P, Kalra L. Indomethacin and cognitive function in healthy elderly volunteers. British Journal of Clinical Pharmacology 1994;38(1):45-51. - PMC - PubMed
Clarke 2003 {published data only}
    1. Clarke R, Harrison G, Richards S. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. Journal of Internal Medicine 2003;254(1):67-75. - PubMed
Gómez‐Isla 2008 {published data only}
    1. Gómez-Isla T, Blesa R, Boada M, Clarimón J, Ser T, Domenech G, et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Disease and Associated Disorders 2008;22(1):21-9. - PubMed
Hayden 2007 {published data only}
    1. Hayden KM, Zandi PP, Khachaturian AS, Szekely CA, Fotuhi M, Norton MC, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. Neurology 2007;69(3):275-82. - PubMed
Ibáñez‐Hernández 2008 {published data only}
    1. Ibáñez-Hernández MG, Macías-Islas MÁ, Zavalza-Gómez AB, Pacheco-Moisés FP, Ortiz Genaro G. Efecto del ibuprofeno y ácido acetilsalicílico sobre el deterioro cognitivo, poder antioxidante total e isoprostanos en suero^ies. Gaceta Medica de Mexico 2008;144(6):497-502. - PubMed
Jonker 2003 {published data only}
    1. Jonker C, Comijs HC, Smit JH. Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiology of Aging 2003;24(4):583-8. - PubMed
Kang 2007 {published data only}
    1. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ 2007;334(7601):987-90. - PMC - PubMed
Kern 2012 {published data only}
    1. Kern S, Skoog I, Ostling S, Kern J, Borjesson-Hanson A. Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women. BMJ Open 2012;2:eoo1288. [DOI: 10.1136/bmjopen-2012-001288] - DOI - PMC - PubMed
Kerst 2002 {published data only}
    1. Kerst AJ. Do NSAIDs prevent Alzheimer's disease? Geneesmiddelenbulletin 2002;36(3):36.
Marini 2013 {published data only}
    1. Marini S, Lucidi G, Bessi V, Padiglioni S, Bracco L, Sorbi S. Does low-dose acetyl-salicylic acid reduce cognitive decline in patient with mild cognitive impairment? Journal of Neurology 2013;260:S165.
May 1992 {published data only}
    1. May FE, Moore MT, Stewart RB, Hale WE. Lack of association of nonsteroidal anti-inflammatory drug use and cognitive decline in the elderly. Gerontology 1992;38(5):275-9. - PubMed
Price 2008 {published data only}
    1. Price JF, Stewart MC, Deary IJ, Murray GD, Sandercock P, Butcher I, et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ 2008;337:a1198. - PMC - PubMed
Rist 2013 {published data only}
    1. Rist PM, Buring JE, Kase CS, Kurth T. Effect of low-dose aspirin on functional outcome from cerebral vascular events in women. Stroke 2013;44(2):432-6. - PMC - PubMed
Silagy 1993 {published data only}
    1. Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clinical Pharmacology and Therapeutics 1993;54(1):84-9. - PubMed
Sonnen 2010 {published data only}
    1. Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010;75(13):1203-10. - PMC - PubMed
Szekely 2008 {published data only}
    1. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008;70(1):17-24. - PMC - PubMed

Additional references

APA 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington (DC): American Psychiatric Association, 1994.
Barnes 2011
    1. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurology 2011;10(9):819-28. - PMC - PubMed
Benedict 1996
    1. Benedict RH, Schretlen D, Groninger L, Dobrashki M, Shpritz B. Revision of the Brief Visuospatial Memory tests: studies of normal performance, reliability, and validity. Psychological Assessment 1996;8(2):145-53.
Brandt 1991
    1. Brandt J. The Hopkins Verbal Learning Test: development of a new verbal memory test with six equivalent forms. Clinical Neuropsychologist 1991;5(2):125-42.
Bresalier 2005
    1. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial. New England Journal of Medicine 2005;352(11):1092-102. - PubMed
Brookmeyer 1998
    1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the united states and public health impact of delaying disease onset. American Journal of Public Health 1998;88:1337-42. - PMC - PubMed
Chui 2007
    1. Chui HC. Subcortical ischaemic vascular dementia. Neurologic Clinics 2007;25(3):717-40. - PMC - PubMed
Clark 1996
    1. Clark CM, Ewbank DC. Performance of the Dementia Severity Rating Scale: a caregiver questionnaire for rating severity in Alzheimer's Disease. Alzheimer's Disease Association Disorders 1996;10:31-9. - PubMed
Cohen‐Mansfield 2000
    1. Cohen-Mansfield J. Nonpharmacological management of behavioural problems on persons with dementia: the TREA Model. Alzheimer's Care Quarterly 2000;1(4):722-7.
Conaghan 2012
    1. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International 2012;32(6):1491-2. - PMC - PubMed
Coteilli 2012
    1. Coteilli M, Manenti R, Zanetti O. Reminiscence therapy in dementia: a review. Maturitas 2012;72(3):203-5. - PubMed
Crump 2013
    1. Crump CJ, Johnson DS, Li YM. Development and mechanism of γ-secretase modulators for Alzheimer's disease. Biochemistry 2013;52(19):3197-216. - PMC - PubMed
Cudaback 2014
    1. Cudaback E, Jorstad NL, Yang Y, Mortine TJ, Keene CD. Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochemical Pharmacology 2014;88(4):565-72. - PMC - PubMed
Cunningham 2015
    1. Cunningham C, Hennessy E. Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimer's Research & Therapy 2015;7(1):33. - PMC - PubMed
Devine 2003
    1. Devine ME, Rands G. Does aspirin affect outcomes in vascular dementia? A retrospective case-notes analysis. International Journal of Geriatric Psychiatry 2003;18(5):425-31. - PubMed
Etminan 2003
    1. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003;327(7407):128. - PMC - PubMed
García Rodríguez 2016
    1. García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PloS One 2016;11(8):e0160046. [DOI: 10.1371/journal.pone.0160046.] - DOI - PMC - PubMed
Gorelick 2010
    1. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Annals of the New York Academy of Sciences 2010;1207:155-62. - PubMed
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime) GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.Available at gradepro.org.
Hawkey 1999
    1. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353(9149):307-14. - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hoe 2005
    1. Hoe J, Katona C, Roch B, Livingston G. Use of the QOL-AD for measuring quality of life in people with severe dementia: the LASER-AD study. Age and Ageing 2005;34(2):130-5. - PubMed
Hoe 2006
    1. Hoe J, Hancock G, Livingston G, Orrell M. Quality of life of people with dementia living in care homes. British Journal of Psychiatry 2006;188(5):460-4. - PubMed
Hoe 2007
    1. Hoe J, Katona C, Orrell M, Livingston G. Quality of life in dementia: care recipient and caregiver perceptions of quality of life in dementia: the LASER-AD study. International Journal of Geriatric Psychiatry 2007;22(10):1031-6. - PubMed
Hoe 2009
    1. Hoe J, Hancock G, Woods B, Callis D, Orrell M. Changes in the quality of life of people with dementia living in care homes. Alzheimer Disease and Associated Disorders 2009;23(3):285-90. - PMC - PubMed
In't Veld 2001
    1. In't Veld BA, Ruitenberg A, Hofman A, Launer LJ, Van Duijin CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and risk of Alzheimer's disease. New England Journal of Medicine 2001;345(21):1515-21. - PubMed
Jack 2013
    1. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology 2013;12(2):207-16. - PMC - PubMed
Jaturapatporn 2012
    1. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD006378.pub2] - DOI - PMC - PubMed
Jellinger 2006
    1. Jellinger KA. Cliniciopathological analysis of dementia disorders in the elderly – an update. Journal of Alzheimer's Disease 2006;9(3):61-70. - PubMed
Katz 1970
    1. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist 1970;10(1):20-30. - PubMed
Kinney 2018
    1. JW Kinney, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2018;4:575-90. - PMC - PubMed
McCullagh 2001
    1. McCullagh C, Craig D, McIllroy P, Passmore P. Risk factors for dementia. Advances in Psychiatric Treatment 2001;7:24-31.
McGeer 1995
    1. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Research Reviews 1995;21(2):195-218. - PubMed
McGeer 1996
    1. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 1996;47(2):425-32. - PubMed
McGeer 1997
    1. McGeer EG, McGeer PL. Innate inflammatory reaction of the brain in Alzheimer disease. McGill Journal of Medicine 1997;3(2):134-41.
McGeer 2000
    1. McGeer PL. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 2000;17(1):1-11. - PubMed
McKhann 1984
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS/ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-44. - PubMed
Morris 1988
    1. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for Alzheimer's disease (CERAD). Clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacology Bulletin 1988;24(4):641–52.. - PubMed
Ozudogru 2012
    1. Ozudogru SN, Lippa CF. Disease modifying drugs targeting b-amyloid. American Journal of Alzheimer's Disease and Other Dementias 2012;27:296-300. - PMC - PubMed
Park 2013
    1. Park JH, Seo SW, Kim C, Kim GH, Noh HJ, Kim ST, et al. Pathogenesis of cerebral microbleeds: in vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Annals of Neurology 2013;73:584-93. - PubMed
Patel 2013
    1. Patel B, Lawrence A, Chung AW, Rich P, Mackinnon AD, Morris RG, et al. Cerebral microbleeds and cognition in patients with symptomatic small vessel disease. Stroke 2013;44(2):356-61. - PubMed
Patricio 2013
    1. Patricio JP, Barbosa JP, Ramos RM, Antunes NF, Mel PC. Relative cardiovascular and gastrointestinal safety of non-selective anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors. Clinical Drug Investigation 2013;33(3):167-83. - PubMed
Prince 2015
    1. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. The world Alzheimer report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. www.alz.co.uk/research/world-report-2015 (accessed 23 April 2020).
Rands 2000
    1. Rands G, Orrell M. Aspirin for vascular dementia. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001296] - DOI - PMC - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Richardson 2007
    1. Richardson JT. Measures of short-term memory: a historical review. Cortex 2007;43(5):635-50. - PubMed
Rogers 1988
    1. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiology of Aging 1988;9(4):339-49. - PubMed
Roh 2014
    1. Roh JH, Lee JH. Recent updates on subcortical ischaemic vascular dementia. Journal of Stroke 2014;16(1):18-26. - PMC - PubMed
Seo 2007
    1. Seo SW, Hwa LB, Kim EJ, Chin J, Sun Cho Y, Yoon U, et al. Clinical significance of microbleeds in subcortical vascular dementia. Stroke 2007;38(6):1949-51. - PubMed
Solomon 2005
    1. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine 2005;352:1071-80. - PubMed
Squire 1979
    1. Squire LR, Wetzel CD, Slater PC. Memory complaint after electroconvulsive therapy: assessment with a new self-rating instrument. Biological Psychiatry 1979;14:791-801. - PubMed
Stewart 1997
    1. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAI use. Neurology 1997;48(3):626-32. - PubMed
Szekely 2004
    1. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004;23(4):159-69. - PubMed
Teng 1987
    1. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. Journal of Clinical Psychiatry 1987;48:314-8. - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdette S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. - PMC - PubMed
Vane 1971
    1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology 1971;231(25):232-9. - PubMed
Vane 1998
    1. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. American Journal of Medicine 1998;104(3A):2S-8S. - PubMed
Varga 2017
    1. Varga Z, Sabzwari SR, Vargova V. Cardiovascular risk of nonsteroidal anti-Inflammatory drugs: an under-recognized public health issue. Cureus 2017;9(4):e1144. - PMC - PubMed
Walter 2014
    1. Walter A, Rocca WA, Mielke MM, Vemuri P, Miller VM. Sex and gender differences in the causes of dementia: a narrative review. Maturitas 2014;79(2):196-201. - PMC - PubMed
Wang 2015
    1. Wang J, Tan L, Wang H, Tan CC, Meng XF, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. Journal of Alzheimer's Disease 2015;44(2):385-96. - PubMed
Wilson 1989
    1. Wilson B, Cockburn J, Baddeley A, Hiorns R. The development and validity of a test battery for detecting and monitoring everyday memory problems. Journal of Clinical and Experimental Neuropsychology 1989;11:855-70. - PubMed
World Health Organization 2012
    1. World Health Organization. Dementia: a Public Health Priority. Geneva: World Health Organization and Alzheimer's Disease International, 2012.
Yaffe 2013
    1. Yaffe K, Falvey C, Harris T, Newman A, Satterfield S, Koster A, et al. Effects of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. BMJ 2013;347:f7051. - PMC - PubMed
Yesavage 1983
    1. Yesavage JA, Brink TL, Rose TL, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research 1983;17(1):37-49. - PubMed

References to other published versions of this review

Jordan 2015
    1. Jordan F, McGuinness B, Murphy K, Passmore P, Kelly JP, Devane D. Aspirin and anti-inflammatory drugs for the prevention of dementia. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD011459] - DOI - PMC - PubMed

Publication types

MeSH terms